Skip to main content
. 2021 Oct 30;23:524–538. doi: 10.1016/j.omtm.2021.10.011

Figure 2.

Figure 2

Cohort of 4 SMA patients with 2 SMN2 copies receiving nusinersen early in life

Longitudinal plots for pNf-H concentrations, Nf-L concentrations, and CMAP values for each individual case (A–D) in this cohort. Red arrows indicate the first nusinersen dose.